Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
20,580 total articles
BIO-key International, a leader in biometric identity and access management solutions, announced that CEO Michael DePasquale will participate in virtual meetings and present at the H.C. Wainwright Global Investment Conference in September 2026. The company's presentation will be available on demand to registered attendees, highlighting its biometri…
Emergent BioSolutions has been awarded a $24 million contract modification by BARDA, part of the U.S. Department of Health and Human Services, to supply its CYFENDUS® anthrax vaccine. This contract supports the U.S. government's ongoing anthrax preparedness efforts amid biological threats. CYFENDUS®, FDA-approved in 2023 for post-exposure prophylax…
Kayne Anderson Energy Infrastructure Fund, Inc. declared a monthly distribution of $0.09 per common share payable on September 30, 2026. The fund focuses on energy infrastructure securities and aims to provide high after-tax returns with an emphasis on cash distributions. Distribution amounts may vary and are subject to Board approval and financial…
Sezzle Inc. announced that Gymshark, Debenhams Group (including its multiple brands), and Follett Higher Education are now offering Sezzle as a payment option at checkout. This expansion comes during a record back-to-school shopping season, providing flexible payment solutions for budget-conscious students and families. With Sezzle's point-of-sale …
3 E Network Technology Group Limited announced that its wholly owned subsidiary secured a $1.2 million sales order for enterprise-grade DDR4 memory chips. This order demonstrates the company's capabilities in hardware supply amid growing IT infrastructure upgrades and provides additional revenue to support its AI infrastructure R&D efforts. The ord…
NorthStrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), announced an expanded three-phase program with Yuva Biosciences to advance four AI-discovered compounds toward lead nomination for developing potential therapies in cardiac diseases and obesity. The program builds upon positive Phase III results and aims to de-risk and narrow ca…
Kala Bio and Virotek announced a letter of intent to establish an exclusive U.S. distribution partnership where Kala will market and distribute Virotek's genetic testing program for ophthalmology. This collaboration aligns with Kala's strategic focus on eye care and provides a near-term commercial revenue opportunity while extending Kala's reach in…
Heidmar Maritime Holdings Corp. reported robust second quarter and first half 2026 results with total revenues of $29.0 million in Q2, a significant increase from $9.6 million in Q2 2025, driven by growth in commercially managed vessels and higher chartering activity. Net income attributable to shareholders rose to $2.2 million in Q2 2026 compared …
Clearmind Medicine Inc. has initiated Phase IIa of its Phase I/IIa clinical trial evaluating CMND-100, a non-hallucinogenic psychedelic-derived therapeutic candidate, for the treatment of Alcohol Use Disorder (AUD). Six patients have been enrolled so far across medical centers in Israel, marking progression into the multiple-dose treatment phase fo…
Vera Therapeutics, a US-based commercial-stage biotech company specializing in autoimmune kidney diseases, will present at the Cantor Global Healthcare Conference and the Morgan Stanley Global Healthcare Conference in September 2026. The company's management aims to engage investors through fireside chats and one-on-one meetings, highlighting their…
Alumis announced that its Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus (SLE) did not meet primary and secondary endpoints in the overall population. However, robust responses in the prespecified interferon gene signature-high (IFNGS-high) subgroup, representing most moderate-to-severe SLE cases, support …
KANZHUN LIMITED, a leading Chinese online recruitment platform, announced the rotation of its president position effective September 1, 2026. Mr. Xu Chen steps down as president but remains as executive director and Chief Marketing Officer, while Mr. Tao Zhang takes over as rotating president alongside his roles as executive director and Chief Tech…
BridgeBio Pharma, a biopharmaceutical company focused on genetic condition medicines, announced that its management will participate in several upcoming healthcare investor conferences in September 2026. These include Wells Fargo, Cantor Global, Morgan Stanley, and Bernstein Insights conferences. The company aims to communicate its developments and…
Ardelyx Inc., a US commercial-stage biopharmaceutical company, has announced its participation in several major investor conferences in New York during September 2026, including Citi, Cantor, and Morgan Stanley healthcare events. The company will host fireside chats and investor meetings, providing updates on its commercial products IBSRELA and XPH…
Streamex Corp., a Nasdaq-listed technology company specializing in tokenization of commodity assets, appointed Laura Kiernan as Head of Investor Relations. Kiernan brings over 30 years of capital markets experience to lead investor relations strategy, aiming to bridge the value of Streamex's platform with market perception. The move supports Stream…
FocalTherics, a leader in robotic focal therapy, announced that its CEO and CFO will present and host investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 15-16, 2026. The company focuses on minimally invasive medical devices leveraging proprietary focused ultrasound technology to treat various …
Telesat Government Solutions, a US-based subsidiary of Telesat Corporation (TSAT), has signed a strategic collaboration with Cailabs US, Inc. to integrate secure, resilient, high-capacity optical space-to-ground connectivity for U.S. Government and allied missions. The partnership aims to combine Telesat's Lightspeed LEO satellite network with Cail…
USBC, a publicly traded technology company focused on tokenized deposits, announced the hiring of Richa Pareek as Chief Product Officer. Pareek brings extensive experience from JPMorgan Chase, Coinbase, and other leading tech firms. Her appointment coincides with the next phase of USBC's product testing and platform development for their blockchain…
Comstock Resources announced a strategic partnership with SOCAR involving the sale of non-operated interests in its Legacy and Western Haynesville assets and Pinnacle Gas Services for $1.65 billion in cash. Additionally, Comstock entered a $450 million drilling joint venture with majority stockholder Jerry Jones to fund drilling of Haynesville well…
Stoke Therapeutics and Biogen presented 4-year clinical data showing sustained improvements in cognition, behavior, and durable seizure reductions with a generally well-tolerated safety profile for zorevunersen, an investigational antisense oligonucleotide targeting the underlying cause of Dravet syndrome. The ongoing global Phase 3 EMPEROR study a…
Kura Oncology, Inc., a biopharmaceutical company specializing in precision cancer medicines, announced that its management will present at three prominent healthcare investor conferences in September 2026. The events include the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Morgan Stanley Global Healthcare Conference. …
Descartes Systems Group announced it has acquired Extensiv, enhancing its warehouse management and omnichannel fulfillment solutions for third-party logistics providers (3PLs) and ecommerce brands. The acquisition strengthens Descartes' Global Logistics Network by integrating AI-powered capabilities to optimize inventory, order management, and fulf…
Unicycive Therapeutics, a clinical-stage biotech company focused on developing treatments for kidney diseases, announced its CEO will present at the upcoming H.C. Wainwright Global Investment Conference. The company is advancing novel therapies including oxylanthanum carbonate for hyperphosphatemia in dialysis patients and UNI-494 for acute kidney …
Ocugen has dosed the first patient in its global Phase 3 registrational trial of OCU410, a one-time modifier gene therapy targeting multiple disease pathways for geographic atrophy secondary to dry age-related macular degeneration (dAMD). The therapy has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation, enabling potential acce…
Invivyd, Inc. has appointed Marc W. Elia as CEO, who was previously Chairman and has driven the company's scientific and corporate strategy. The company is nearing the completion of Phase 3 studies (DECLARATION and LIBERTY) for its COVID-19 monoclonal antibody candidate VYD2311, with top-line data expected by end of Q3 2026. Invivyd is preparing re…
